Get the Stockscreener App
948.45
2.72%
-26.51
After Hours:
949.00
0.55
+0.06%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $948.45, with a volume of 2.96M.
It is down -2.72% in the last 24 hours and down -0.51% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$974.96
Open:
$974.07
24h Volume:
2.96M
Relative Volume:
0.92
Market Cap:
$845.77B
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
34.14
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
-1.54%
1M Performance:
-0.51%
6M Performance:
+2.61%
1Y Performance:
+26.22%
1-Day Range:
$947.51
$980.00
1-Week Range:
$947.51
$996.49
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
948.45 | 869.41B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
221.32 | 535.63B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
201.55 | 358.55B | 62.82B | 3.62B | 17.82B | 2.0331 |
AZN
Astrazeneca Plc
|
182.85 | 283.06B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
146.03 | 277.42B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
GLP-1 battle heats up between Eli Lilly and Novo Nordisk - Yahoo Finance UK
Lilly to invest extra $4.5B across Indiana manufacturing - Manufacturing Dive
Omada Health (OMDA) Q1 2026 Earnings Transcript - The Globe and Mail
Lilly's obesity pill tops 7,000 prescriptions in fourth week, signals modest uptake - Reuters
Will Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There. - The Motley Fool
Eli Lilly and Company 8-K Filing May 2026 – SEC Document Details, Registered Securities & Company Information - Minichart
Here is Why Eli Lilly (LLY) is One of the Best Stocks to Buy for the Next 15 Years - Insider Monkey
Eli Lilly (LLY) issues $9.0B multi‑tranche notes; Centessa redemption clause included - Stock Titan
Eli Lilly Stock a Strong Buy in 2026 as Mounjaro, Zepbound Demand Fuels Blowout Growth and Analyst Upside - International Business Times Australia
Eli Lilly's (NYSE:LLY) Earnings Are Weaker Than They Seem - Yahoo Finance
Major Legacy Investor Makes a Powerful Move in Eli Lilly Stock - TipRanks
Eli Lilly Shareholders Back Board, Maintain Governance Structure - TipRanks
Omada Health joins Eli Lilly employer weight loss program - Investing.com
Eli Lilly revives dollar market with $9bn M&A financing - GlobalCapital
Eli Lilly (NYSE: LLY) investors back board, keep supermajority rules - Stock Titan
44% of surveyed GLP-1 patients pay over $250 a month as Omada adds Lilly channel - Stock Titan
Lilly Endowment Inc. sells Eli Lilly (NYSE:LLY) stock worth $15.75 million - Investing.com
Omada Health Joins Lilly Employer Connect, Expanding Its Access Pathways for GLP-1 Care as Patients Seek More Lifestyle Support - Yahoo Finance UK
Lilly Endowment trims Eli Lilly (LLY) stake with 15,828-share open sale - Stock Titan
Forget Eli Lilly: These 2 Stocks Have More Upside - The Motley Fool
What the FDA's Latest Proposal Means for Lilly, Novo, and Hims - MarketBeat
Is Eli Lilly and Company (LLY) One of the Best Strong Buy Growth Stocks to Buy Right Now? - Insider Monkey
Cantor Fitzgerald Lifts PT on Eli Lilly and Company (LLY) on Q1 Earnings Call - Insider Monkey
Eli Lilly Now Has the World's Best-Selling Drug -- But Does That Make the Stock a No-Brainer Buy? - Yahoo Finance
Lilly and Regeneron Advance Obesity Combo Bet as Key Tirzepatide Trial Reaches Completion - TipRanks
Novo (NVO) and Lilly (LLY) Stocks Jump as Weight-Loss Pills Reveal Monster Market Potential - TipRanks
Lilly announces additional $4.5B investment at LEAP District manufacturing site - dailyjournal.net
Lilly Invests $4.5B to Indiana Manufacturing Site - PharmTech.com
Novo and Lilly gain on signs weight-loss pills could expand the market - Reuters
Wolfe Research Says Market Reaction on Eli Lilly (LLY) Foundayo Report Appears Overdone - Insider Monkey
Eli Lilly’s Mounjaro Becomes World’s Top-Selling Drug - The Business of Fashion
Lilly announces another $4.5 billion investment, opens first LEAP facility - reporter.net
Eli Lilly: Additional $4.5bn to support its industrial scale-up - marketscreener.com
America's Weight-Loss Drug Boom Is Going Global -- Heard on the Street -- WSJ - Moomoo
The Zacks Analyst Blog Highlights Eli Lilly, Western Digital, Vertiv Holdings and AgEagle - Yahoo Finance Singapore
Eli Lilly To Invest $4.5 Billion More In Indiana Manufacturing Sites - Benzinga
My Top Obesity Stock to Buy and Hold - AOL.com
Lilly grants Korean biotech 1STBIO access to proprietary AI drug discovery models - koreabiomed.com
Video: Blue Whale backs Eli Lilly's mass market appeal - Citywire
Eli Lilly (LLY) Reports Q1 2026 Revenue Surge of 56% Following FDA Approval of Foundayo - Insider Monkey
Lilly looks to sell about $8B of debt to fund acquisitions - Indianapolis Business Journal
Quarterly Sales Reach $8.7 Billion, Eli Lilly’s Mounjaro Becomes New Blockbuster Drug King - NAI500
Eli Lilly's Mounjaro overtakes Merck's Keytruda as world's top-selling drug - Business Standard
Change of leadership in the pharmaceutical world! Eli Lilly and Co's Mounjaro surpasses Merck & Co's Keytruda to become the world's best-selling drug. - 富途牛牛
Change of the top-selling drug! Eli Lilly and Co's Mounjaro surpasses Merck & Co's Keytruda to become the world's best-selling drug. - 富途牛牛
Lilly unveils new genetic medicine facility in Lebanon LEAP District and $4.5 billion investment - WFYI
Lilly’s Mounjaro overtakes Keytruda as world’s top-selling drug - The Boston Globe
Eli Lilly: Files for Eight Part Notes Offerin - Moomoo
Eli Lilly Advances As Inflammatory Bowel Disease Drug Reinforces Long-Term Confidence - Yahoo Finance
Top Research Reports for Eli Lilly, Western Digital & Vertiv - Yahoo Finance
[144] ELI LILLY & Co SEC Filing - Stock Titan
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
0.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):